

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Caduceus Software Systems Corp.

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: 1540 Atwood Ave. # 19652

Address 2: Johnston, RI 02919

Address 3: _____

Phone: 401-648-0695

Email: info@caduceussoftware.net

Website(s): www.caduceussoftware.net

IR Contact

Address 1: _____

Address 2: _____

Address 3: _____

Phone: _____

Email: _____

Website(s): _____

3) Security Information

Trading Symbol: CSOC

Exact title and class of securities outstanding: Caduceus Software Systems Corp. Common Stock

CUSIP: 12763A109

Par or Stated Value: \$0.001

Total shares authorized: 850,000,000 as of: 03/31/17

Total shares outstanding: 794,200,000 as of: 03/31/17

Additional class of securities (if necessary):

Trading Symbol: _____

Exact title and class of securities outstanding: _____

CUSIP: _____

Par or Stated Value: _____

Total shares authorized: _____ as of: _____

Total shares outstanding: _____ as of: _____

Transfer Agent

Name: Island Stock Transfer

Address 1: 15500 Roosevelt Blvd.

Address 2: Suite 301

Address 3: Clearwater, FL 33760

Phone: 727-289-0010

Is the Transfer Agent registered under the Exchange Act?* Yes: ☒ No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

None

B. Any jurisdictions where the offering was registered or qualified;

None

C. The number of shares offered;

None

D. The number of shares sold;

None

E. The price at which the shares were offered, and the amount actually paid to the issuer;

None

F. The trading status of the shares; and

N/A

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

N/A

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

Financial Statements are incorporated by reference to the Quarterly Report for the Nine Months ended December 31, 2016 filed on March 31, 2016.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

- A. a description of the issuer's business operations;

Development, sales and support of software for medical office management and operations, including recording of patient history, symptoms and integration of digital images as part of the patient record.

- B. Date and State (or Jurisdiction) of Incorporation:

Incorporated on December 13, 2006 in Nevada

- C. the issuer's primary and secondary SIC Codes;

7371 and 7373

- D. the issuer's fiscal year end date;

March 31

- E. principal products or services, and their markets;

Provide and install medical practice management software to medical professionals.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company operates utilizing the current offices of its officers, directors, and outsourced professionals, servers are housed in third party hosting facilities, and the Company sells through direct contact with potential customers, onsite presentations, and via the web.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

- A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Richard Tang – CEO, Director

Anna Tang – Control Person

Erwin Vahlsing, Jr. - CFO

- B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- Richard Tang 59.1%
273 Murphy Drive W
Delta, BC V4M 3P1

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Richard Tang certify that:

1. I have reviewed this Quarterly Report as of December 31, 2016 of Caduceus Software Systems Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 1, 2017

/s/ Richard Tang CEO

I, Erwin Vahlsing, Jr. certify that:

1. I have reviewed this Annual Report as of December 31, 2016 of Caduceus Software Systems Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 1, 2017

/s/ Erwin Vahlsing, Jr. CFO

Caduceus Software Systems Corp.

Quarterly Report

For the Six Months Ended

December 31, 2016

Caduceus Software Systems, Inc.
Quarterly Report
For the Nine Months Ended December 31, 2016

Item 1. Name of Issuer and Address of Executive Offices

Item 2. Shares Outstanding

Item 3. Interim Financial Statements

Unaudited Balance Sheets at December 31, 2016 and March 31, 2016

Unaudited Statements of Operations for the nine months ended December 31, 2016 and 2015

Unaudited Statements of Stockholders Deficit for the nine months ended December 31, 2016 and 2015

Unaudited Consolidated Statements of Cash Flows for the nine months ended December 31, 2016 and 2015

Notes to the Unaudited Consolidated Financial Statements

Item 4. Management Discussion and Analysis

Item 5. Legal Proceedings

Item 6. Default on Senior Securities

Item 7. Other Information

Item 8. Exhibits

Item 9. Certifications

Item 1 Name of Issuer and Address of Executive Offices

The Company was incorporated under the laws of the State of Nevada, U.S. on December 13, 2006 under the name Bosco Holdings Inc. On March 1, 2011, the Company changed its name from Bosco Holdings Inc. to Caduceus Software Systems Corp. The Company was in the development stage as defined under Accounting Codification Standard (“ASC”) 915, “Development Stage Entities”, and its efforts were primarily devoted marketing and distributing laminate flooring to the wholesale and retail markets throughout North America.

On June 9, 2011, the Company entered into a Licensing Agreement for the exclusive license to software optimized for use in the medical industry for patient management, patient appointment scheduling, physician memorandum recording, medical symptom and ailment recording and digital image recording. The Company is now in the business of providing medical software to medical professionals. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. Effective with this filing, the Company will not continue to report as “Development Stage” as permitted by recent changes in the ASC’s.

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at December 31, 2016, and for all periods presented herein, have been made.

The results of operations for the period ended December 31, 2016 are not necessarily indicative of the operating results for future periods.

We are located at 1530 Atwood Ave. #19652, Johnston, RI 02919. Our telephone number is (401) 648-0685, our fax number is (401) 648-0699, our e-mail address is info@caduceussoftware.net, and our homepage on the world-wide web is at www.caduceussoftware.com.

Item 2 Shares outstanding at December 31, 2016*Preferred Series Stock; par value \$0.0001*

Authorized Shares:	50,000,000
Shares Issued and Outstanding:	None
Freely tradable shares:	0
Total number of beneficial shareholders:	0
Total number of shareholders of record:	0

Common Shares; par value \$0.0001

Authorized Shares:	850,000,000
Shares Issued and Outstanding:	794,200,000
Freely tradable shares:	
Total number of beneficial shareholders:	
Total number of shareholders of record:	

Item 3 Interim Unaudited Financial Statements

Unaudited Balance Sheets at December 31, 2016 and March 31, 2016	F-1
Unaudited Statements of Operations for the nine months ended December 31, 2016 and 2015	F-2
Unaudited Statements of Stockholders Deficit for the nine months ended December 31, 2016 and 2015	F-3
Unaudited Statements of Cash Flows for the nine months ended December 31, 2016 and 2015	F-4
Footnotes to the Statements of December 31, 2016	F-5 to F-10

CADUCEUS SOFTWARE SYSTEMS CORP.
BALANCE SHEET
(Unaudited)

	Nine Months Ended December 31, 2016	Year Ended March 31, 2016
<u>ASSETS</u>		
Current assets:		
Cash	\$ -	\$ -
Total current assets	-	-
Fixed and intangible assets:		
Furniture and fixtures	-	-
Leasehold improvements	-	-
Software systems	575,000	575,000
Website	18,000	18,000
Total fixed and intangible assets	593,000	593,000
Accumulated amortization and depreciation	(290,906)	(233,624)
Fixed and intangible assets, net	302,094	359,376
Total assets	\$ 302,094	\$ 359,376
<u>LIABILITIES AND STOCKHOLDERS DEFICIT</u>		
Current liabilities:		
Accounts payable and accrued expenses	269,611	239,136
Loans from officer	73,105	72,205
Notes payable - current	5,011,354	4,913,854
Total current liabilities	5,354,070	5,225,196
Total liabilities	5,354,070	5,225,196
Commitments and contingencies	-	-
Stockholders' deficit		
Common stock - \$0.001 par value, authorized - 850,000,000 shares; issued and outstanding - 794,200,000 and 794,200,000 shares, respectively	794,200	794,200
Additional paid-in capital	4,507,704	4,507,704
Accumulated deficit	(10,353,880)	(10,167,724)
Total stockholders' deficit	(5,051,976)	(4,865,820)
Total liabilities and stockholders' deficit	\$ 302,094	\$ 359,376

See accompanying notes to the consolidated financial statements

CADUCEUS SOFTWARE SYSTEMS CORP.
STATEMENTS OF OPERATIONS
(Unaudited)

	For the three months ended		For the nine months ended	
	December 31, 2016	December 31, 2015	December 31, 2016	December 31, 2015
Revenues	\$ -	\$ -	\$ -	\$ -
Cost of Sales				
Cost of goods sold	17,968	17,968	53,906	53,906
Inventory adjustments	-	-	-	-
Discounts	-	-	-	-
Shipping costs (net of billings)	-	-	-	-
Cost of sales	<u>17,968</u>	<u>17,968</u>	<u>53,906</u>	<u>53,906</u>
Gross profit	(17,968)	(17,968)	(53,906)	(53,906)
Operating expenses:				
Selling expenses	-	-	-	-
General and administrative	128,275	-	128,875	158,350
Depreciation and amortization	1,125	-	3,375	2,250
Total operating expenses	<u>129,400</u>	<u>-</u>	<u>132,250</u>	<u>160,600</u>
Loss from operations	<u>(147,368)</u>	<u>(17,968)</u>	<u>(186,156)</u>	<u>(214,506)</u>
Total other expenses	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Net loss applicable to common stock holders	<u>\$ (147,368)</u>	<u>\$ (17,968)</u>	<u>\$ (186,156)</u>	<u>\$ (214,506)</u>
Per share data				
Net Loss per share - basic and diluted	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>
Weighted average number of shares outstanding- basic and diluted	<u>794,200,000</u>	<u>761,700,000</u>	<u>793,194,536</u>	<u>738,284,699</u>

See accompanying notes to the consolidated financial statements
F-2

CADUCEUS SOFTWARE SYSTEMS CORP.
STATEMENTS OF STOCKHOLDERS' DEFICIT
(Unaudited)

	Common Stock (\$.001 par value)		Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Deficit
	Shares	Amount			
<u>Balance, FYE March 31, 2015</u>	276,700,000	\$ 276,700	\$ 4,869,954	\$ (9,873,800)	\$ (4,727,146)
Issuance of stock for: Compensation	517,500,000	517,500	(362,250)	-	155,250
Net loss	-	-		(293,924)	(293,924)
<u>Balance, FYE March 31, 2016</u>	<u>794,200,000</u>	<u>794,200</u>	<u>4,507,704</u>	<u>(10,167,724)</u>	<u>(4,865,820)</u>
Net loss	-	-		(186,156)	(186,156)
<u>Balance, December 31, 2016</u>	<u>794,200,000</u>	<u>\$ 794,200</u>	<u>\$ 4,507,704</u>	<u>\$ (10,353,880)</u>	<u>\$ (5,051,976)</u>

See accompanying notes to the consolidated financial statements
F-3

CADUCEUS SOFTWARE SYSTEMS CORP.
STATEMENTS OF CASH FLOWS
(Unaudited)

	For the nine months ended	
	December 31, 2016	December 31, 2015
Cash flows from operating activities:		
Net loss	\$ (186,156)	\$ (214,506)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	57,281	56,156
Common stock issued for services	-	145,500
Changes in operating asset and liability account balances:		
Conversion of accounts payable to notes payable	97,500	
Accounts payable and accrued expenses	30,475	5,751
Total adjustments	<u>185,256</u>	<u>207,407</u>
Net cash used in operating activities	<u>(900)</u>	<u>(7,099)</u>
Cash flows from investing activities		
Net cash used in investing activities	<u>-</u>	<u>-</u>
Cash flows from financing activities:		
Proceeds from officer loans	900	7,099
Net cash provided by financing activities	<u>900</u>	<u>7,099</u>
Net increase (decrease) in cash	-	-
Cash at beginning of year	<u>-</u>	<u>-</u>
Cash at end of year	<u>\$ -</u>	<u>\$ -</u>
Supplemental Schedule of Cash Flow Information:		
Cash paid for interest	<u>\$ -</u>	<u>\$ -</u>
Cash paid for income taxes	<u>\$ -</u>	<u>\$ -</u>
Supplemental Schedules of Noncash Investing and Financing Activities:		
Conversion of notes payable and accrued interest into common stock	<u>\$ -</u>	<u>\$ -</u>
Common stock issued for services	<u>\$ -</u>	<u>\$ -</u>

See accompanying notes to the consolidated financial statements

CADUCEUS SOFTWARE SYSTEMS CORP.
Notes to the Financial Statements
December 31, 2016 and 2015
(Unaudited)

1. NATURE OF OPERATIONS

The Company was incorporated under the laws of the State of Nevada, U.S. on December 13, 2006 under the name Bosco Holdings Inc. On March 1, 2011, the Company changed its name from Bosco Holdings Inc. to Caduceus Software Systems Corp. The Company was in the development stage as defined under Accounting Codification Standard (“ASC”) 915, “Development Stage Entities”, and its efforts were primarily devoted marketing and distributing laminate flooring to the wholesale and retail markets throughout North America. On June 9, 2011, the Company entered into a Licensing Agreement for the exclusive license to software optimized for use in the medical industry for patient management, patient appointment scheduling, physician memorandum recording, medical symptom and ailment recording and digital image recording. The Company is now in the business of providing medical software to medical professionals. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. Effective with this filing, the Company will not continue to report as “Development Stage” as permitted by recent changes in the ASC’s.

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at December 31, 2016, and for all periods presented herein, have been made.

The results of operations for the period ended December 31, 2016 is not necessarily indicative of the operating results for future periods.

2. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended December 31, 2016, the Company had a net loss of \$186,156. As of December 31, 2016, the Company has a working capital deficit of \$5,354,070. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the continued financial support from its management, its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and its ability to grow operations and to achieve a level of profitability. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes and proceeds from sub-licensing agreements until such time that funds provided by operations are sufficient to fund working capital requirements. However, there can be no assurance that these arrangements will be sufficient to fund its ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Cash and Cash Equivalents

For purposes of Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Included in these estimates are assumptions about collection of accounts receivable, impairment of intangibles, useful life of property and equipment, stock based compensation, beneficial conversion of convertible notes payable, deferred income tax asset valuation allowances, and valuation of derivative liabilities.

Foreign Currency Translation

The financial statements are presented in United States dollars. In accordance with ASC-830, "Foreign Currency Matters", foreign denominated monetary assets and liabilities are translated into their United States dollar equivalents using foreign exchange rates which prevailed at the balance sheet date. Non-monetary assets and liabilities are translated at the exchange rates prevailing on the transaction date. Revenue and expenses are translated at average rates of exchange during the period. Gains or losses resulting from foreign currency transactions are included in results of operations.

Fair Value of Financial Instruments

The carrying value of cash, accounts payable and accrued liabilities, loans from related party and loan payable approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management's opinion the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. At December 31, 2016, a full-deferred tax asset valuation allowance has been provided and no deferred tax asset has been recorded.

Basic and Diluted Loss Per Share

The Company computes loss per share in accordance with ASC-260, "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.

The Company has no potential dilutive instruments and accordingly basic loss and diluted loss per share are equal.

Long-Lived Assets

The Company has adopted ASC-360, "Property, Plant and Equipment" which requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of

intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC-360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

Research and Development

The Company accounts for research and development costs in accordance with the ASC-730, "Research and Development". Under ASC-730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenditures of \$0 for the period from December 31, 2016 and 2015.

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. At December 31, 2016, the Company has cash in the amount of \$0. The Company places its cash and temporary cash investments with credit quality institutions

Revenue Recognition

The Company will recognize revenue in accordance with ASC-605, "Revenue Recognition," which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts.

Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.

Advertising

The Company follows the policy of charging the costs of advertising to expenses incurred. The Company incurred \$0 in advertising costs during the years ended December 31, 2016 and 2015.

Stock-based Compensation

The Company records stock based compensation in accordance with the guidance in ASC-718, "Compensation - Stock Compensation," which requires the Company to recognize expenses related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award.

Recent accounting pronouncements

The FASB has issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The Company has not yet determined the effect of the adoption of this standard.

The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The Company has not yet determined the effect of the adoption of this standard and it is not expected to have a material impact on the Company's consolidated financial position and results of operations.

In August 2014, the FASB issued a new accounting standard which requires management to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern for each annual and interim reporting period. If substantial doubt exists, additional disclosure is required. This new standard will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. The Company expects to adopt this new standard for the fiscal year ending March 31, 2017 and the Company will continue to assess the impact on its consolidated financial statements.

On June 10, 2014, the Financial Accounting Standards Board ("FASB") issued update ASU 2014-10, Development Stage Entities (Topic 915). Amongst other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from US GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and shareholder's equity, (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015, however entities are permitted to early adopt for any annual or interim reporting period for which the financial statements have yet to be issued. The Company has elected to early adopt these amendments and accordingly have not labeled the financial statements as those of a development stage entity and have not presented inception-to-date information on the respective financial statements.

In January 2015, the FASB issued ASU No. 2015-01, "Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items." This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. We do not expect the adoption of ASU 2015-01 to have a material effect on our financial position, results of operations or cash flows.

In April 2015, FASB issued Accounting Standards Update ("ASU") No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, is to simplify presentation of debt issuance costs by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The ASU does not affect the recognition and measurement guidance for debt issuance costs. For public companies, the ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

In July 2015, FASB issued Accounting Standards Update ("ASU") No. 2015-11, "Inventory (Topic 330): Simplifying the Measurement of Inventory" more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards (IFRS). The amendments in this ASU do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of this Update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. For public business entities, this ASU is effective for fiscal years beginning after December 15,

2016, including interim periods within those fiscal years. For all other entities, this ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The amendments in this ASU should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.

In August 2015, FASB issued Accounting Standards Update (“ASU”) No.2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date” defers the effective date ASU No. 2014-09 for all entities by one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in Update 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. All other entities should apply the guidance in Update 2014-09 to annual reporting periods beginning after December 15, 2018, and interim reporting periods within annual reporting periods beginning after December 15, 2019. All other entities may apply the guidance in ASU No. 2014-09 earlier as of an annual reporting period beginning after December 15, 2016, including interim reporting periods within that reporting period. All other entities also may apply the guidance in Update 2014-09 earlier as of an annual reporting period beginning after December 15, 2016, and interim reporting periods within annual reporting periods beginning one year after the annual reporting period in which the entity first applies the guidance in ASU No. 2014-09. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.

In August 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-15, “Interest - Imputation of Interest (Subtopic 835-30).” ASU 2015-15 provides guidance as to the presentation and subsequent measurement of debt issuance costs associated with line of credit arrangements. We do not expect the adoption of ASU 2015-15 to have a material effect on our financial position, results of operations or cash flows.

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

4. EQUITY

Equity consists of the following:

- **Common Stock** Par value \$0.001 per share
850,000,000 Authorized
- **Preferred Stock** Par value \$0.001 per share
50,000,000 Authorized
Can be issued in one or more series at the discretion of the Board of Directors
Board can assign preferences, conversion rights, etc. at their discretion

Common Stock

As of December 31, 2016, there are 794,200,000 of common stock issued and outstanding

Preferred Stock

As of December 31, 2016, there are no series of preferred shares designated and 0 shares issued and outstanding

5. LOANS PAYABLE

As of December 31, 2016, the Company owes an unrelated third party \$15,579. The loan is non-interest bearing, and due on demand.

As of December 31, 2016, the Company owes \$10,321 to two unrelated third parties. The loans are non-interest bearing, and are due on demand.

As of December 31, 2016, the Company owes \$10,321 to two unrelated third parties. The loans are non-interest bearing, and are due on demand.

As of December 31, 2016, the Company owes \$4,869,954 in connection with a previously discontinued acquisition of the medical management software (Caduceus MMS) it was licensing. In connection with the cancellation of the license agreement, the Company assumed the debt owed by Sygnit to a third party. The loan is non-interest bearing, and is due on demand.

During the quarter ended December 31, 2016, the Company reclassified invoices totaling \$97,500 from accounts payable to Notes Payable. The 3 invoices for accounting services of \$30,000 per year, and accrued interest of \$2,500 per year, had been converted to notes payable as of their due dates, however, they were left in the accounts payable balance for convenience. The invoices and notes date back to fiscal years 2012, 2013, and 2014. The Company has reclassified them to properly report as notes.

6. RELATED PARTY TRANSACTIONS

As of December 31, 2016, the Company owes \$29,603 to its previous president and CEO for unsecured advances made to the Company from 2011 through 2012. The loan is non-interest bearing, due upon demand and unsecured.

As of December 31, 2016, the current CEO, president and director of the Company has loaned the Company \$52,802 to cover operating costs. The loan is non-interest bearing, due upon demand and unsecured.

7. CONTINGENCY

The Company disputes charges with RBSM LLP (predecessor auditor) for the review of the Form 8-K and correspondence with the successor auditor during 2008, in amount of \$3,025. The Company examined the invoices, and decided that charges for the review of the 8K and correspondence with the successor auditor are excessive.

9. SUBSEQUENT EVENTS

The Company has determined that there were no subsequent events up to and including the date of the issuance of these financial statements that warrant disclosure or recognition in the financial statements.

Item 4 Management Discussion and Analysis

THE FOLLOWING ANALYSIS OF THE RESULTS OF OPERATIONS AND FINANCIAL CONDITION OF THE COMPANY SHOULD BE READ IN CONJUNCTION WITH THE CONSOLIDATED FINANCIAL STATEMENTS, INCLUDING THE NOTES THERETO OF THE COMPANY, CONTAINED ELSEWHERE IN THIS REPORT.

Forward-looking statements in this report may prove to be materially inaccurate. In addition to historical information, this report contains forward-looking information that involves risks and uncertainties. The words "may", "will", "expect", "anticipate", "continue", "estimate", "project", "intend" and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those included within the forward-looking statements as a result of factors, including the risks described above and factors described elsewhere in this report.

Strategy

Our goal is to be a leading and innovative provider of Software Services to medical practices around the world. Our **Caduceus MMS**® software provides a full suite of services for management of the entire medical practice bridging the gap of many software offerings by providing modular components that unite both the Electronic Health Record ("EHR") and the Electronic Medical Billing ("EMB") to streamline the management of any practice, anywhere in the world.

Our overall strategy utilizes our core competencies in the design, deployment and management of software and systems to provide installations on small local networks in the medical practice office, to larger systems in medical facilities. With our software, there can, with proper planning, be nominal costs incurred as offices upgrade and gear up for larger client bases.

SIGNIFICANT ACCOUNTING POLICIES

A summary of significant accounting policies is included in Note 3 to the unaudited consolidated financial statements included in the Company's Financial Statements for the nine months ended December 31, 2016 attached hereto. Management believes that the application of these policies on a consistent basis enables the Company to provide useful and reliable financial information about the company's operating results and financial condition.

Results of operations

Nine months ended December 31, 2016 and 2015.

Revenue and Cost of Sales

As we are continuing the development of our software suite, we have not begun to sell our software. We expect to begin generating revenue within the next twelve to eighteen months.

In both nine-month periods ended December 31, 2016 and 2015, we recorded \$53,906 in depreciation expense for the software which had been capitalized.

Selling, general and administrative expenses

General and administrative expenses consist primarily of consulting compensation and expenses for executive, administrative and operations, including legal and accounting fees, and facility and office-related costs such as Internet and web hosting, and depreciation expense.

For the nine-month ended December 31, 2016, these expenses decreased \$28,100 or 17.5% to \$132,250 from \$160,600 for the nine-months ended December 31, 2015.

The decrease in SG&A was primarily the result of decreased costs connected with our public filings and state filing fees. All other SG&A expenses were nominal when comparing the nine month to nine month numbers.

Interest Expense

Interest expense consists of interest accrued on loans and notes payable.

There was no accrual or payment of interest as none of the notes or loans carries interest.

Net Loss

For the nine-month ended December 31, 2016, the Company had a loss of \$186,156 as compared to a loss of \$214,506 for the nine-months ended December 31, 2015 a decrease of \$82,256 or 38.3%.

The significant difference for the nine months as compared to the same period last year is mainly due to the decreased SG&A expense recorded during the current nine months.

Income Taxes

No provision for federal and state income taxes has been recorded as the Company incurred net operating losses since inception. The net operating losses will be available to offset any future taxable income. Given the Company's operating history, losses incurred to date and the difficulty in accurately forecasting future results, management does not believe that the realization of the potential future benefits of these carry forwards meets the criteria for recognition of a deferred tax asset required by generally accepted accounting principles. Accordingly, a full 100% valuation allowance has been provided.

Liquidity and Capital Resources

Cash and cash equivalents were \$0 at December 31, 2016. Net cash used in operating activities of \$900 was provided through an officer loan.

At December 31, 2016, the Company had a working capital deficit of \$5,354,070. The Company made no capital expenditures during the nine months ended December 31, 2016.

During the nine months ended December 31, 2016 and the fiscal year ended March 31, 2016, the Company issues the following shares of common stock:

In April 2015, the Company issued a total of 485,000,000 common shares at a price of \$0.0003 per share for compensation of consultants for continued software development.

In October 2015, the Company issued 32,500,000 common shares at a price of \$0.0003 per share for accounting and financial services.

During the nine months ended December 31, 2016 and the fiscal year ended March 31, 2016, the Company issued demand notes in the amount of \$7,099 and \$15,000 respectively to a shareholder of the Company. During the same periods, the Company repaid \$0 and \$0 respectively in demand notes to an officer of the Company.

Notes and Various Overhead Items impacting liquidity

- 1) Accounting, filing and SEC related administration fees remained \$30,000 per year from 2012 to 2016 inclusive for XBRL Associates, Inc. under the various engagement letters signed by the Company. Invoices reflecting same were received for each fiscal year between 2012 to 2016 along with a total of 4 promissory notes and debt notes.
 - a. For 2012 a debt note in the amount of \$32,000 was executed by the Company under which XBRL Associates is permitted to convert into common shares at a strike price of 0.001 per share.
- 2) Website design costs incurred was \$18,000 payable to Anna Tang.
- 3) Salary continued at \$40,000 per year to the Company president evidenced by an affiliated debt note, and was converted to restricted certificates of 75,000,000 shares per year. Of these years 5 have been issued and the latest have not been due to reaching the maximum authorized share limit.
- 4) Hardware and IT infrastructure hosting costs of \$31,000 are due to Tango in the form of a note, convertible at par (\$0.001) and broken down \$18,000 and \$13,000 for the years 2015 and 2016 respectively.
- 5) Transfer Agent fees remain fixed at \$100 per month which is paid by management, and booked as debt. A note has been issued each year which includes a penalty for the arrearages to Island Stock Transfer. These notes have not been issued or converted to stock due to the Company being close to the maximum authorized limit for share issuances.
- 6) Arrearages and bills from our SEC counsel as well as fees due to OTC Markets and costs incurred remaining current with the State of Nevada State (including penalties and interest) have been paid for by Richard Tang as cash loans and recorded as debt owed to an officer or director. These notes have not been issued or converted to stock due to the Company being close to the maximum authorized limit for share issuances.
- 7) Rent of office space is in arrears from 2012 and prior in the amount of \$3,000 per year and is included as part of notes for each unpaid year. These liabilities were, reassigned to current management from the previous management, Derrick Gidden and Oswald Huggins and is convertible into common stock at \$0.001 per share, and remains unissued due to the Company being close to the maximum authorized limit for share issuances.

- 8) Alexander Dannikov, the original president, was originally issued 3,000,000 shares of common stock in March 2007. These shares were in exchange for his investment in the Company to cover the costs of the legal and accounting work for the original SB filings. The shares were included as part of the original SB.
- a. Subsequently, in April 2008, the Company executed a 5:1 forward stock split which increased the holding to 15,000,000 shares.
 - b. In March 2011, the Company executed a second forward split of 8:1 increasing the shares to 120,000,000 shares.
 - c. In June 2011, Mr. Dannikov assigned 63,800,000 of his shares to Sygnit Corp, to license the software developed by Sygnit Corp.
 - d. The Company name, Bosco Holdings at the time, was subsequently changed to Caduceus Software Systems.
 - e. Mr. Dannikov remained the holder of 56,200,000 shares on certificate (1148) until his resignation at which time the certificate was bifurcated and reassigned to Ankyro Solutions (26,200,000 shares) and Avatele Group (30,000,000 shares) by mutual agreement for a purchase price of \$1.00 and fully executed stock powers.
- 9) 130,000,000 restrict shares of Sygnit stock (cert 1166) was issued for services, licenses and programming work perform from the time Caduceus Software Systems was renamed to 2014 inclusively. After the required time frame (holding period), the certificate was restructured into individual certificates in the names of the following individuals: J. Sewell, C. Donalds, N. Donalds, Tango, Richard Tang and Sygnit itself. The remaining 60,000,000 shares of Sygnit stock Cert 1166 was sold for \$1 and transferred by stock powers to Maximum Ventures Holdings (30,000,000), and Harmony Ridge (30,000,000) as Sygnit agreed other programmers and administrators were needed to continue the project. For the payment of the \$1, the 60,000,000 shares referenced above was transferred to the two parties with the intention that they would assist in completing the work with Caduceus. As the cost of depositing their shares was deemed too expensive at the time, both C. Donalds (10,000,000) and N. Donalds (10,000,000) stock certificates were transfer as a “gift” to Richard Tang via fully executed stock powers after receiving approval from a special Annual General Meeting held by Sygnit. These shares became part of the control block held by Richard Tang subsequent to his appointment as president and CEO of the Company.

Item 5. Legal proceedings

None

Item 6. Defaults upon senior securities

None

Item 7. Other information

None

Item 8. Exhibits

None

Certification of Chief Executive Officer
Item 9.1

I, Richard Tang, certify that:

1. I have reviewed this Quarterly Disclosure Statement of Caduceus Software Systems Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for the periods presented in this disclosure statement.

April 1, 2017

/s/ Richard Tang

Chief Executive Officer

Certification of Chief Financial Officer
Item 9.2

I, Erwin Vahlsing, Jr., certify that:

1. I have reviewed this Quarterly Disclosure Statement of Caduceus Software Systems Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for the periods presented in this disclosure statement.

April 1, 2017

/s/ Erwin Vahlsing, Jr.
Chief Financial Officer